Geotropism and Oncogenic Potential of HPV Infections in Cohort Study Populations in Vojvodina, North Region of Serbia
Abstract
Background/Aim: Geotropism of the human papillomavirus (HPV) represents the heterogeneous distribution of different genotypes worldwide. Aim of this study was to evaluate the prevalence of the human papillomavirus (HPV) infection in women from Vojvodina, Serbia, according to cytological status and pathological changes of cervix - dysplasia and cancer.
Methods: The research was conducted as a retrospective study at the Oncology Institute of Vojvodina and the Institute of Public Health of Vojvodina (IPHV). Data from the medical records of female patients treated for cervical intraepithelial neoplasia or cervical cancer at the Department of Gynaecology, Clinic for Surgical Oncology, Oncology Institute of Vojvodina in Sremska Kamenica in the period from 2016 to 2021 were used, as well as the laboratory findings of the IPHV for a group of patients with normal cytological results of the Papanikolau (PAPA) smear.
Results: A total of 731 women, from 20 to 82 years of age, with different cytological results were enrolled. 567 samples were classified as NILM, while 164 samples belong to a group of abnormal histopathology (LSIL/HSIL/cervical cancer). The HPV genotyping assay was performed using the EUROArray HPV test to detect 30 HPV genotypes. In the overall number with normal cytological findings, HPV infection was verified in 242 (42.7 %) patients, of which 135 (55.8 %) were verified with high risk HPV, while 76 (31.4 %) were verified with a mixed group of HPV (Low risk/High risk HPV). Most prevalent genotypes were HPV 16, 31, 53, 51 and 18 in NILM cytological status. In the samples with the abnormal histopathology, the most prevalent genotypes were HPV 16, 33, 31 and 56, while 18 and 39 were equally verified. Genotype 16 was the most prevalent in the examined sample, with a higher prevalence in higher-grade histopathological findings: 18.8 % in LSIL, 31.9 % in HSIL and 75.0 % in cervical cancer samples. Infection with multiple associated genotypes of HPV was not correlated with histopathology. By comparing histopathological diagnosis and age, older patients had higher-grade lesions.
Conclusion: Based on the estimated oncogenic potential of HPV genotypes as well as their prevalence in presented sample, it can be concluded that the nine-valent HPV vaccine for genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58 would have the potential to prevent HPV infection and the incidence of precancerous lesions and cervical cancer in about 85 % of women. Observing trends in the prevalence of HPV, especially HR HPV genotypes, can be important in the further strategy of applying secondary and primary prevention, as well as the application of HPV detection as part of co-testing or considering the introduction of HPV testing in the initial screening program.
References
1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 Sep;189(1):12-9.
2. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination-review of current perspectives. J Oncol 2019 Oct 10;2019:3257939. doi: 10.1155/2019/3257939.
3. Bruni L, Albero G, Serrano,B, Mena M, Gómez D, Muñoz J, et al [Internet]. ICO/IARC Information Centre on HPV and Cancer (HPVInformation Centre). Human papillomavirus and related diseases in Serbia. Summary Report 10 December 2018. [Cited: 1-Jan-2020]. Available at: https://hpvcentre.net/statistics/reports/SRB.pdf.>
4. The Seventy-third World Health Assembly [Internet]. Global strategy to accelerate the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020–2030. [Cited: 1-Jan-2021]. Available at: https://www.who.int/publications/i/item/9789240014107.>
5. International Agency for Research on Cancer (IARC). IARC handbook of cancer prevention. cervical cancer screening, Vol.10. Lyon, France: IARC Press; 2005.
6. Beyazit F, Sılan F, Gencer M, Aydin B, Paksoy B, Unsal MA, et al. The prevelance of human papillomavirus (HPV) genotypes detected by PCR in women with normal and abnormal cervico-vaginal cytology. Ginekol Pol 2018;89(2):62-7.
7. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010 Dec 15;202(12):1789-99.
8. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007 Jul;7(7):453-9.
9. Bansal D, Elmi AA, Skariah S, Haddad P, Abu-Raddad LJ, Al Hamadi AH, et al. Molecular epidemiology and genotype distribution of Human Papillomavirus (HPV) among Arab women in the State of Qatar. J Transl Med 2014 Nov 26;12:300. doi: 10.1186/s12967-014-0300-4.
10. Kaliterna V, Andelinović S, Pejković L, Hofman ID. Human papillomavirus DNA typing in the cervical specimens among women of Split and Dalmatian County. Coll Antropol 2007 Apr;31 Suppl 2:79-82.
11. Milutin-Gašperov N, Sabol I, Halec G, Matovina M, Grce M. High-risk HPV among Croatian women, Coll Antropol 2007 Apr;31 Suppl 2:89–96.
12. Haręża DA, Wilczyński JR, Paradowska E. Human papillomaviruses as infectious agents in gynecological cancers. Oncogenic properties of viral proteins. Int J Mol Sci 2022 Feb 5;23(3):1818. doi: 10.3390/ijms23031818.
13. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010 Nov;11(11):1048-56.
14. Martins TR, Mendes de Oliveira C, Rosa LR, de Campos Centrone C, Rodrigues CLR, Villa LL, et al. HPV genotype distribution in Brazilian women with and without cervical lesions: correlation to cytological data. Virol J 2016 Aug 12;13:138. doi: 10.1186/s12985-016-0594-3.
15. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, et al; VALGENT Study Group. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 2013 May;51(5):1458-64.
16. Milosevic V, Mandic A, Kovacevic G, Natasa N, Petrovic V [Internet]. Prevalence of HPV genotypes among women in Vojvodina - Distribution of HPV among healthy population EUROGIN 2019, Monaco 4-7.12.2019. [Cited: 1-Jan-2021]. Available at: https://www.eurogin.com/content/dam/markets/aest/eurogin/pdfs/2023/EUROGIN2023_Abstracts_FreeCommunicationsSessions.pdf.>
17. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer 2009 Oct;45(15):2632-9.
18. Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control 2013 Sep;24(9):1653-60.
19. Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, et al; VIVIANE Study Group. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int J Cancer 2016 May 15;138(10):2428-38.
20. Mirabello L, Clarke MA, Nelson CW, Dean M, Wentzensen N, Yeager M, et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Viruses 2018 Feb 13;10(2):80. doi: 10.3390/v10020080.
21. Arezzo F, Cormio G, Loizzi V, Cazzato G, Cataldo V, Lombardi C, et al. HPV-negative cervical cancer: a narrative review. Diagnostics (Basel) 2021 May 26;11(6):952. doi: 10.3390/diagnostics11060952.
22. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices Cancer Cytopathol 2015;123(5):282–8.
23. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, et al. Human papillomavirus genotypes in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012;131(10):2349–59.
24. Li N, Franceschi S, Howell-Jones R, Snijders PJF, Clifford GM. Human papillomavirus genotype distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological genotype and year of publication. Int J Cancer 2011;128(4):927–35.
25. Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human papillomavirus-negative cervical cancer: a comprehensive review. Front Oncol 2021 Feb 17;10:606335. doi: 10.3389/fonc.2020.606335.
26. Holl K, Nowakowski AM, Powell N, McCluggage WG, Pirog EC, Collas DeSouza S, et al. Human papillomavirus prevalence and genotype-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int J Cancer 2015;137(12):2858–68.
27. Petry KU, Liebrich C, Luyten A, Zander M, Iftner T. Surgical staging identified false HPV-negative cases in a large series of invasive cervical cancers. Papillomavirus Res 2017;4:85–9.
28. Cancer Genome Atlas Research Network; Albert Einstein College of Medicine; Analytical Biological Services; Barretos Cancer Hospital; Baylor College of Medicine; Beckman Research Institute of City of Hope; et al. Integrated genomic and molecular characterization of cervical cancer. Nature 2017 Mar 16;543(7645):378-84.
29. Pirog EC, Lloveras B, Molijn A, Tous S, Guimerà N, Alejo M, et al. HPV prevalence and genotypes in different histological subgenotypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Modern Pathol 2014;27(12):1559–67.
30. Pirog EC, Park KJ, Kiyokawa T, Zhang X, Chen W, Jenkins D, et al. Gastric-genotype adenocarcinoma of the cervix: tumor with wide range of histologic appearances. Adv Anat Pathol 2019;26(1):1–12.
31. Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): A new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 2018;42(2):214–26.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).